← SynDRA
FOSAMPRENAVIR
SynDRA canonical compound SYN0016568 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Mechanism of action | HIV protease inhibitor |
|---|
| Indication | human immunodeficiency virus (HIV-1) |
|---|
| Disease area | infectious disease |
|---|
All known targets
- HIV PR
- gag-pol
- pol
- CYP3A4
- TBXAS1
- CTSD
- protease
- HIV-1 protease
Mechanisms of action (all sources)
- protease inhibitor
- HIV PR INHIBITOR
- pol INHIBITOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Drug classes
- HIV Protease Inhibitors
- Anti-Bacterial Agents
- Anti-HIV Agents
- Anti-Infective Agents
- Anti-Retroviral Agents
- Antibiotics, Antitubercular
- Antitubercular Agents
- Antiviral Agents
- Enzyme Inhibitors
- Protease Inhibitors
- Viral Protease Inhibitors
- Protease Inhibitor
ATC classes
- J05A · DIRECT ACTING ANTIVIRALS
Cross-references
Synonyms
- FOSAMPRENAVIR CALCIUM
- LEXIVA
- Lexiva
- fos-amprenavir
- GW433908
- GW-433908
- telzir
- amprenavir phosphate
- fosamprenavir calcium
- GW433908A
- Telzir
- Amprenavir phosphate
- Fosamprenavir [INN]
- GW 433908
- VX-175
- Fosamprenavir (INN)
- Lexiva (TM)
- Lexiva (TN)
- Telzir (TN)
- Telzir(TM)
- GW433908A (*Sodium Salt*)
- GW433908G (*Calcium Salt*)
- FOS-APV
- WOU1621EEG
- CHEBI:82941
- GW-908
- fosamprenavirum
- RefChem:921785
- DTXCID7028271
- C25H36N3O9PS
- HSDB 7340
- UNII-WOU1621EEG
- MFCD09955118
- GW908 cpd
- VX175 cpd
- FOSAMPRENAVIR [MI]
- Epitope ID:231725
- FOSAMPRENAVIR [HSDB]
Reported adverse events
- Angioedema
- Fatigue
- Headache
- Nausea
- Rash
- Vomiting
- Abdominal pain
- Myocardial infarction
- Nephrolithiasis
Look up FOSAMPRENAVIR in the interactive SynDRA portal →